US FDA approves Amgen’s colorectal cancer therapy: Lumakras (Sotorasib) and Vectibix (Panitumumab) for Metastatic Colorectal Cancer
The U.S. Food and Drug Administration (FDA) has approved Amgen’s combination therapy of Lumakras (sotorasib)
The U.S. Food and Drug Administration (FDA) has approved Amgen’s combination therapy of Lumakras (sotorasib)
The FDA has approved Grafapex (treosulfan) in combination with fludarabine as a conditioning regimen for
Key Highlights: Clinical Trial Findings: DESTINY-Breast06 The FDA’s decision was based on results from the
Explore the latest innovations in cancer treatment that are shaping the future of oncology.